News

Press Releases
Back to Press Releases >
BioRestorative Therapies Engages Consulting Firm to Develop Strategic Partnerships in Japan and China
08/18/2014
BioRestorative Therapies
BioRestorative Therapies Engages Consulting Firm to Develop Strategic Partnerships in Japan and China

JUPITER, Fla. (August 18, 2014) - BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced the engagement of Tokyo-based Solution Partners Ltd. to develop strategic alliances in Japan and China for the Company's technologies. The agreement includes introductions to potential strategic partners and other alliance candidates, with the goal of expansion and development of the Company's ThermoStem® program, the Company's stem cell delivery device used in connection with the Company's brtx-DISCTM program and the Company's brtx-C Cosmetic program.

Solution Partners, founded by Masami Ishigaki in 2000, is an official supporting member of Tokyo Metropolitan Hospital Association. Mr. Ishigaki has served in various financial positions at, among others, Suntory, Novartis Pharma (Japan), and LVMH Group (Guerlain Japan and Celine Japan).

"Solution Partners has a strong track record of success in identifying and negotiating strategic alliances in Japan and China, and we are very excited to engage Mr. Ishigaki and his firm to identify business possibilities for us," said Mark Weinreb, BioRestorative Therapies' Chief Executive Officer. "These Asian markets are very large, and represent significant potential opportunities for our proprietary stem cell programs. We look forward to continuing our work on ThermoStem® and brtxDISC™ in the U.S. while expanding the worldwide market for our therapies. In addition, Mr. Ishigaki's experience in the cosmetics field is expected to support our goal of licensing brtx-C Cosmetic technologies to skincare companies."

About Solution Partners Ltd.

Solution Partners has provided quality improvement programs for medical care and nursing systems, hospital infection control, hospital information systems and recruitment services for professional medical staff. It is also engaged in marketing and sales support for genetic testing for cancer, developed by Japanese company Genescience Ltd. in Japan and in China.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

brtxDISC™ (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:
LHA
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

# # #

BioRestorative Therapies: A Stem Cell Biotechnology Company